Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma
Early Phase 1
Completed
- Conditions
- Pyoderma GangrenosumPyoderma VegetansPyodermaPyoderma Gangrenosum Surrounding Surgical Stoma
- Interventions
- Biological: Monoclonal antibody (Mab) sB24M
- First Posted Date
- 2021-05-20
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- SWISS BIOPHARMA MED GmbH
- Target Recruit Count
- 10
- Registration Number
- NCT04895566
- Locations
- 🇱🇻
Contract Research Organization, RÄ«ga, Latvia
© Copyright 2025. All Rights Reserved by MedPath